This is a significant dilutive event for a $6M market cap biotech. The company has now tapped its ATM facility for a total potential of ~$6.9M since April 2025. Monitor for actual share sales under this new tranche and any further cash runway updates. The persistent ATM usage signals ongoing cash burn without near-term revenue catalysts.
Price Chart
Executive Summary
Enveric Biosciences filed a prospectus supplement to offer up to $2,425,000 of common stock under its existing ATM agreement with H.C. Wainwright. The company has already sold $4,483,711.04 through the same ATM facility prior to this filing. This represents continued equity dilution for a micro-cap biotech with a $6M market cap.
Key Facts
- Enveric filed a prospectus supplement on June 9, 2026 to offer up to $2,425,000 of common stock via its ATM agreement with H.C. Wainwright
- Prior to this filing, the company had already sold $4,483,711.04 through the same ATM facility since the agreement date of April 9, 2025
- The new offering represents approximately 40% of the company's $6M market cap in potential additional dilution
- Total potential ATM sales since inception now stand at $6,908,711.04 (already sold $4.48M + new $2.425M tranche)
Financial Impact
Up to $2,425,000 in new common stock issuance, representing ~40% of current $6M market cap in additional dilution
Risk Factors
- Continued dilution from ATM sales could pressure the stock price
- Micro-cap biotech with no disclosed revenue or near-term catalysts to offset dilution
- Potential for further ATM tranches if cash needs persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027976 |
| Exhibit: ex5-1.htm | 0001493152-26-027976 |
| Document: 0001493152-26-027976-index-headers.html | 0001493152-26-027976 |
| Document: 0001493152-26-027976-index.html | 0001493152-26-027976 |
| Document: 0001493152-26-027976.txt | 0001493152-26-027976 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $1.48 $1.46 | ▲ +1.35% | ▼ −0.63% | $1.38 (+6.76%) |
Jun 9, 2026 19w ago | 8-K | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.38 (+14.81%) |
Jun 9, 2026 19w ago | 424B5 | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.38 (+14.81%) |
May 29, 2026 21w ago | 8-K | $2.26 $1.38 | ▲ +38.94% | ▲ +37.64% | $1.38 (+38.94%) |
May 15, 2026 23w ago | 8-K | $2.25 $1.48 | ▼ −34.22% | ▼ −36.34% | $1.38 (−38.67%) |
Apr 23, 2026 26w ago | S-3 | $5.04 $2.22 | ▲ +55.95% | ▲ +59.98% | $1.38 (+72.62%) |
Apr 14, 2026 27w ago | DEFA14A | $2.03 $2.52 | ▲ +24.14% | ▲ +18.09% | $1.38 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers